By: Alana Hippensteele, Editor From: pharmacytimes.com The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer, according to preclinical studies.1 Led by Walter and Eliza Hall Institute researchers, the new study used breast cancer cells taken from patients and demonstrated that venetoclax was effectively able to kill sleeping, or ‘senescent,’ cancer cells.1 The results from …